ALLMedicine™ Hereditary Hemorrhagic Telangiectasia Center

May 20th, 2022 - Neurologic manifestations in hereditary hemorrhagic telangiectasia include an increased incidence of brain abscesses and ischemic strokes due to paradoxic embolization in addition to a wide spectrum of symptoms and complications due to typical bra...

May 7th, 2022 - Injection of cyanoacrylate glue for hereditary hemorrhagic telangiectasia.|2022|Anciaux M,Lebreton JP,Tonnerre D,Leclerc J,Dufour X,|

Apr 30th, 2022 - The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis ...

Apr 29th, 2022 - Pial arteriovenous fistula (AVF) is a vascular fistulous disease in which the cerebral pial artery and vein are directly connected without the intervening nidus within a sub-pial space. Multi-hole pial AVFs, wherein multiple feeders flow into one ...

Apr 27th, 2022 - The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis ...

Apr 30th, 2022 - The gastrointestinal hamartomatous polyposis syndromes are rare, autosomal dominant disorders associated with an increased risk of benign and malignant intestinal and extraintestinal tumors. They include Peutz-Jeghers syndrome, juvenile polyposis ...

Sep 8th, 2020 - Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (VMs). These result in chronic bleeding, acute hemorrhage, and c...

Apr 7th, 2020 - Hereditary hemorrhagic telangiectasia and liver involvement: Vascular liver diseases: position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFEF), and ERN-rare liver.|2020|Silv...

Mar 8th, 2022 - The most common symptom of the hereditary hemorrhagic telangiectasia (HHT) disease is epistaxis. HHT is characterized by vascular (blood vessel) malformations, of the skin and mucus membranes of the nose (telangiectasia), gastrointestinal track, b...

Nov 22nd, 2021 - Background and Rationale HHT has an estimated prevalence of 1 in 5000, affecting children and adults, in multiple organs. The disease is characterized by the presence of vascular malformations (VMs), including arteriovenous malformations (AVMs) of...

Oct 19th, 2021 - Antiangiogenic drugs, such as bevacizumab, are a new treatment strategy in Hereditary Hemorrhagic Telangiectasia (HHT). Its systemic administration in patients with HHT improves liver damage-related symptoms and epistaxis (cases reported and on-go...

Aug 24th, 2021 - This study is a double-blinded, placebo-controlled, 8-week randomized clinical trial investigating the efficacy of timolol gel in the management of epistaxis in adults with HHT. The Specific Aims are to determine in adults with HHT-associated epis...

Jul 15th, 2020 - This is a single-arm, open-label study that will investigate the efficacy and safety profile of pomalidomide in patients with genetically-documented Hereditary Hemorrhagic Telangiectasia (defined by characteristic mutations in Eng, Alk-1 or Smad-4...

Sep 30th, 2020 - The Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines were published on September 8, 2020.[1] Management of Epistaxis To reduce HHT-related epistaxis, use moisturizing topical therapies that humidify the nasal mucosa. Con...

Sep 30th, 2020 - The Second International Hereditary Hemorrhagic Telangiectasia (HHT) Guidelines were published on September 8, 2020.[1] Management of Epistaxis To reduce HHT-related epistaxis, use moisturizing topical therapies that humidify the nasal mucosa. Con...

Sep 10th, 2020 - NEW YORK (Reuters Health) - New guidelines provide updated advice on managing epistaxis and vascular malformations and new recommendations for managing gastrointestinal (GI) bleeding, anemia, pediatric care, and pregnancy and delivery. The expert ...

Sep 10th, 2020 - NEW YORK (Reuters Health) - New guidelines provide updated advice on managing epistaxis and vascular malformations and new recommendations for managing gastrointestinal (GI) bleeding, anemia, pediatric care, and pregnancy and delivery. The expert ...

Jun 18th, 2020 - Bevacizumab has shown efficacy in the treatment of hereditary hemorrhagic telangiectasia (HHT), a rare, progressive bleeding disorder for which there are currently no approved therapies. The finding comes from the InHIBIT-Bleed trial, results from...